Patient Characteristics

Treatment Arms Were Balanced in the Phase 3 NOVA Study of ZEJULA1

Reference: 1. Mirza MR, Monk BJ, Herrstedt J, et al; ENGOT-OV16/NOVA investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164.

Study design

STUDY DESIGN

See the clinical rigor behind the pivotal trial design for ZEJULA

View Trial Info

Efficacy summary

EFFICACY DATA

View PFS in the gBRCAmut & non-gBRCAmut cohorts

View Efficacy

Safety data

SAFETY DATA

Learn about the safety and tolerability of ZEJULA

See Safety

Pivotal trial

PIVOTAL TRIAL

See the pivotal phase 3 trial publication

Access Publication